Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

IPA Best of Health Awards

- PMLiVE

Eli Lilly’s Jaypirca granted FDA accelerated approval for non-Hodgkin lymphomas

Approximately 18,740 new cases of CLL have been diagnosed in the US this year

- PMLiVE

Amgen’s supplemental Biologics License Application for Blincyto approved by FDA

The approval for the leukaemia drug was supported by additional data from two phase 3 studies

- PMLiVE

Sanofi and Innate Pharma expand cancer therapeutics collaboration

The partnership is aimed at exploring the potential of natural killer cells therapeutics in oncology

- PMLiVE

ICR twin study indicates childhood leukaemia begins in the womb

The study, published in Leukemia, will help clinicians advise parents of twins with ALL

Daiichi Sankyo logo

Daiichi gets breakthrough status for pre-NDA leukaemia drug

Quizartinib could have an advantage over rival drug Rydapt

National Institute for Health and Care Excellence NICE logo

NICE to look again at Pfizer’s Besponsa after appeal

The blood cancer medicine was originally turned down on cost-effectiveness grounds

- PMLiVE

Novartis gets EU nod for leukaemia drug Rydapt

The FLT3 inhibitor adds to its US approval in AML

National Institute for Health and Care Excellence NICE logo

NICE set to reject Pfizer’s leukaemia drug Besponsa

Firm plans to appeal the final appraisal determination on its orphan drug

- PMLiVE

FDA clears Pfizer’s leukaemia drug Besponsa

The breakthrough treatment is the first CD22-targeted ADC to be approved in the US

- PMLiVE

NICE rejects Pfizer’s antibody drug for leukaemia

Trial shows no survival benefit from Besponsa compared to current treatment

- PMLiVE

Juno gives up on lead CAR-T drug after deaths

ROCKET trial for leukaemia patients ended

Celgene building

Celgene bags US priority review for cancer metabolism drug

First approval for enasidenib could be just six months away

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links